MigraineMind research summary
Efficacy, tolerability and barriers to the use of anti-CGRP medications among migraine patients in Egypt: real world experience.
Front Neurol | 2026
Observational studySummary
This study evaluated the real-world use of anti-CGRP therapies in Egypt. Researchers focused on effectiveness, tolerability, barriers to access, and treatment adherence. Eighty migraine patients participated, including 62 with chronic and 18 with episodic migraine. These patients received Erenumab, Galcanezumab, or Rimegepant. After treatment, 54 patients, or 68%, had a favorable response. They experienced over 50% reduction in monthly migraine days and headache severity. Significant improvements were noted in HIT-6 and MIDAS scores. Treatment tolerability was generally good, although 35 patients discontinued treatment. Reasons included satisfactory improvement, lack of improvement, or cost. Relapse occurred in 42% of discontinuation cases. This study provides real-world insights into the effectiveness of anti-CGRP therapies. It highlights clinical improvement, good tolerability, and challenges in treatment access and adherence. Further controlled studies are recommended to confirm these findings and address barriers. Clinical relevance: This research shows that anti-CGRP therapies can significantly improve migraine outcomes in Egypt.
Key Learning Points
- Anti-CGRP therapies can lead to significant reductions in the number of migraine days and headache severity for many patients in Egypt.
- A majority of patients reported a favorable response to treatment, with 68% experiencing over 50% improvement.
- While treatment tolerability was generally good, 35 patients discontinued therapy for various reasons, including cost and lack of improvement.
- Relapse rates were notable, with 42% of those who discontinued treatment experiencing a return of migraines.
- Access to these therapies remains a challenge, highlighting the need for further studies to improve treatment adherence and availability.
Related migraine research topics
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.